• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

information for practice

news, new scholarship & more from around the world


advanced search
  • gary.holden@nyu.edu
  • @ Info4Practice
  • Archive
  • About
  • Help
  • Browse Key Journals
  • RSS Feeds

The dark side of weight loss drugs: Ozempic’s surprising hidden cost

SD | FellowshipBard
SD | FellowshipBard

GLP-1 weight-loss drugs like Ozempic and Wegovy are often celebrated as game-changing solutions—but new research reveals a surprising social twist. People who lose weight using these medications may actually face more judgment than those who lose weight through diet and exercise—or even those who don’t lose weight at all. The stigma seems rooted in a perception that these drugs are an “easy way out,” creating a double bind where individuals are judged both for their weight and for how they choose to manage it.

Posted in: News on 05/11/2026 | Link to this post on IFP |
Share

Primary Sidebar

Categories

Category RSS Feeds

  • Calls & Consultations
  • Clinical Trials
  • Funding
  • Grey Literature
  • Guidelines Plus
  • History
  • Infographics
  • Journal Article Abstracts
  • Meta-analyses - Systematic Reviews
  • Monographs & Edited Collections
  • News
  • Open Access Journal Articles
  • Podcasts
  • Video

© 1993-2026 Dr. Gary Holden. All rights reserved.

gary.holden@nyu.edu
@Info4Practice